Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 4/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5322359 | 0.82 | CCNA2 (0.40) | CCNA2CDK2CCNA1 | |
| SCHEMBL6344162 | 0.76 | CCNA2 (0.39) | CCNA2CDK2CCNA1ERN1 | |
| SCHEMBL6335694 | 0.76 | ALDH1A1 (0.37) | ERN1 | |
| SCHEMBL6342720 | 0.76 | PKM (0.34) | ERN1 | |
| SCHEMBL6335267 | 0.74 | CYP1A2 (0.42) | — | |
| SCHEMBL6341505 | 0.73 | CCNA2 (0.43) | CCNA2CDK2CCNA1ERN1 | |
| SCHEMBL12599615 | 0.71 | — | — | |
| SCHEMBL14436063 | 0.71 | CCNA2 (0.36) | CCNA2CDK2CCNA1 | |
| SCHEMBL10734331 | 0.71 | ALDH1A1 (0.36) | ERN1 | |
| SCHEMBL6826015 | 0.70 | CCNA2 (0.40) | CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171350-A1 | Benzhydryl derivatives | FUJISAWA PHARAMACEUTICAL CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1456201-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003053957-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171350-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | CCNA2 2233/4885CDK2 2274/4885CCNA1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.